Latest Healthcare News

Imricor Medical Systems reported significant regulatory and commercial progress in Q2 CY25, including CE mark approvals and expanded clinical trials, while maintaining a strong cash position.

Advanced Health Intelligence Ltd (AHI) reports robust commercial progress and strategic funding moves in Q1 2025 despite ongoing ASX trading suspension and recent NASDAQ delisting. Key partnerships and technology validations position the company for a strong global scale-up.

Bod Science Limited reports a dramatic reduction in half-year losses alongside revenue growth driven by a strategic shift to THC products. The company remains under a Deed of Company Arrangement with key corporate actions pending shareholder approval.

BlinkLab is advancing its FDA 510(k) clinical trials for autism and ADHD diagnostics, completing its U.S. autism pilot phase and expanding European ADHD recruitment. A recent $7.66 million capital raise supports these efforts as the company targets regulatory approvals in 2026.

Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.

Singular Health has landed a pivotal $2 million US pilot contract with Provider Network Solutions and completed an $8 million capital raise, advancing its medical imaging platform’s regulatory and product development milestones.

Oneview Healthcare reported a €4 million cash outflow in Q2 2025, driven by restructuring and lower R&D credits, while securing new US hospital contracts and expanding AI-powered care solutions.

Echo IQ has secured a strategic collaboration with the Mayo Clinic Platform and raised $17.3 million, advancing its AI-driven cardiology tools towards FDA clearance and US commercial scale.

Universal Biosensors reports a $1.59 million improvement in operating cash outflows for Q2 2025, maintaining $2.55 million in cash as it advances commercialization across blood, wine, and water testing markets.

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.

Aumake Limited reports a robust 50% revenue increase to $39 million for FY25, driven by improving China-Australia trade relations. The company unveils a strategic pivot and corporate restructuring to sharpen its focus on profitable growth and brand incubation.

Island Pharmaceuticals reported promising Phase 2a/b trial results for its dengue drug ISLA-101 and secured a strategic acquisition of the broad-spectrum antiviral Galidesivir, bolstering its pipeline and balance sheet.